Drug Profile
Azacitidine - Pfizer
Alternative Names: 5-azacytidine; Aza-C; Azacytidine; BMS-986345; CC-486; Ladakamycin; NS-17; NSC-102816; Onureg; Oral-Aza; U-18496; VIDAZA; VidazaLatest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Developer AbbVie; Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb; Celgene Corporation; Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Karolinska University Hospital; Kirby Institute for infection and immunity in society; Medical University of South Carolina; Nippon Shinyaku; Pfizer; University Hospital Regensburg; University of Bologna; University of California, San Diego; University of Colorado at Denver; University of Kansas Medical Center; University of Leipzig; University of Texas M. D. Anderson Cancer Center; University of Utah; Washington University School of Medicine; Weill Cornell Medical College
- Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Antimetabolites; DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Phase III T-cell lymphoma
- Phase II Fallopian tube cancer; Graft-versus-host disease; HER2 negative breast cancer; Leukaemia; Nasopharyngeal cancer; Non-small cell lung cancer; Ovarian cancer; Peripheral T-cell lymphoma; Peritoneal cancer
- Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Large granular lymphocytic leukaemia; Lymphoid leukaemia; Renal cancer; Solid tumours
- No development reported Lymphoma; Multiple myeloma
Most Recent Events
- 30 Jan 2024 Medical University of South Carolina and Celgene completes a phase-I trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03450343)
- 08 Jan 2024 Celgene completes a phase I trial in Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in Australia and USA (PO) (NCT04887857)
- 31 Dec 2023 Beigene and Celgene Corporation terminates the license and supply agreement covering REVLIMID and VIDAZA as part of the settlement agreement